PROPOSe:Proclarix血液检测在前列腺癌活检决策中的真实世界前瞻性研究
PROPOSe是一项在10个中心前瞻性纳入457例PSA 2-10 ng/ml、直肠指检正常且前列腺体积≥35 cm³男性的真实世界研究,评估Proclarix血液检测辅助活检决策的准确性。结果显示,Proclarix对临床有意义前列腺癌(GG≥2)的敏感性为91%,特异性显著高于%fPSA和ERSPC风险计算器;在mpMRI融合活检亚组中,Proclarix密度在同等97%敏感性下特异性达33%。结论认为Proclarix可作为有价值的排除工具,单独或联合mpMRI减少不必要活检。
要点
- Proclarix对csPCa(GG≥2)敏感性91%,特异性优于%fPSA和ERSPC风险计算器。
- 在mpMRI融合活检亚组,Proclarix密度在97%敏感性下特异性为33%。
- Proclarix可作为排除工具,单独或联合mpMRI减少不必要的前列腺活检。
核心结论
- 在常规使用场景中,Proclarix能准确区分临床有意义前列腺癌与无或非临床有意义前列腺癌。
- Proclarix是前列腺癌诊断流程中有价值的排除工具,可单独或联合mpMRI使用。
研究设计与样本
- 10个临床中心前瞻性纳入457例接受前列腺活检的男性,PSA 2-10 ng/ml、直肠指检正常、前列腺体积≥35 cm³。
- 允许经直肠超声引导和mpMRI引导活检技术,血清样本在研究结束时盲法检测。
主要发现
- Proclarix风险评分对csPCa(GG≥2)的敏感性为91%(n=362)。
- Proclarix特异性高于%fPSA(22% vs 14%;差异=8% [95%CI 2.6-14%],p=0.005)。
- Proclarix特异性高于ERSPC风险计算器(22% vs 15%;差异=7% [95%CI 0.7-12%],p=0.028)。
- 在mpMRI融合活检亚组(n=121),Proclarix风险评分特异性显著高于PSA密度(26% vs 8%;差异=18% [95%CI 7-28%],p<0.001)。
- 在同等97%敏感性下,Proclarix密度特异性为33% [95%CI 23-43%]。
临床怎么用
- 对于PSA 2-10 ng/ml、直肠指检正常且前列腺体积≥35 cm³的男性,可用Proclarix辅助活检决策。
- Proclarix可作为排除工具,单独或联合mpMRI使用,以减少不必要的前列腺活检。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate-specific antigen (PSA)-based detection of prostate cancer (PCa) often leads to negative biopsy results or detection of clinically insignificant PCa, more frequently in the PSA range of 2-10 ng/ml, in men with increased prostate volume and normal digital rectal examination (DRE). OBJECTIVE: This study evaluated the accuracy of Proclarix, a novel blood-based diagnostic test, to help in biopsy decision-making in this challenging patient population. DESIGN, SETTING, AND PARTICIPANTS: Ten clinical sites prospectively enrolled 457 men presenting for prostate biopsy with PSA between 2 and 10 ng/ml, normal DRE, and prostate volume ≥35 cm3. Transrectal ultrasound-guided and multiparametric magnetic resonance imaging (mpMRI)-guided biopsy techniques were allowed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Serum samples were tested blindly at the end of the study. Diagnostic performance of Proclarix risk score was established in correlation to systematic biopsy outcome and its performance compared with %free PSA (%fPSA) and the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculator (RC) as well as Proclarix density compared with PSA density in men undergoing mpMRI. RESULTS AND LIMITATIONS: The sensitivity of Proclarix risk score for clinically significant PCa (csPCa) defined as grade group (GG) ≥2 was 91% (n = 362), with higher specificity than both %fPSA (22% vs 14%; difference = 8% [95% confidence interval {CI}, 2.6-14%], p = 0.005) and RC (22% vs 15%; difference = 7% [95% CI, 0.7-12%], p = 0.028). In the subset of men undergoing mpMRI-fusion biopsy (n = 121), the specificity of Proclarix risk score was significantly higher than PSA density (26% vs 8%; difference = 18% [95% CI, 7-28%], p < 0.001), and at equal sensitivity of 97%, Proclarix density had an even higher specificity of 33% [95% CI, 23-43%]. CONCLUSIONS: In a routine use setting, Proclarix accurately discriminated csPCa from no or insignificant PCa in the most challenging patients. Proclarix represents a valuable rule-out test in the diagnostic algorithm for PCa, alone or in combination with mpMRI. PATIENT SUMMARY: Proclarix is a novel blood-based test with the potential to accurately rule out clinically significant prostate cancer, and therefore to reduce the number of unneeded biopsies.
引用
- Steuber T, Heidegger I, Kafka M, et al. PROPOSe: A Real-life Prospective Study of Proclarix, a Novel Blood-based Test to Support Challenging Biopsy Decision-making in Prostate Cancer. Eur Urol Oncol. 2021. PMID: 33422560. doi:10.1016/j.euo.2020.12.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。